Weight loss jabs Mounjaro: the honest guide

You've heard about the jabs — here's what is actually in the pen

Picture yourself standing in a pharmacy queue, having read everything about Mounjaro jabs online and still feeling like the basics haven't been explained properly. That is where most people start. The pen itself is a pre-filled KwikPen, each containing four weekly doses. You inject it once a week into the fatty tissue of your abdomen, thigh or upper arm, rotating the site each time. There is no mixing, no measuring: a click and a hold is all the technique required.

What makes Mounjaro different from other weight loss jabs is its mechanism. Most GLP-1 medicines, like other injectable weight loss treatments, act on a single gut-hormone receptor. Tirzepatide (the active ingredient in Mounjaro) activates both the GIP receptor and the GLP-1 receptor simultaneously. The combined effect slows gastric emptying and signals fullness to the brain through two distinct pathways. Appetite falls noticeably, and for most people it falls more than they expect. You can read more about tirzepatide's mechanism and evidence base if you want the pharmacology in detail.

Storage is straightforward: keep the pen in the fridge, ideally in the door where it is easy to grab, and bring it to room temperature before your injection day. The exact duration a pen can safely spend outside the fridge is printed in the Patient Information Leaflet; always check that rather than relying on a general figure online.

The trial results behind the Mounjaro weight loss jab headlines

The numbers quoted in the press come from a real trial programme. SURMOUNT-1 was a 72-week study involving 2,539 adults with obesity and no type 2 diabetes, published in the New England Journal of Medicine. At the 15 mg maintenance dose, average body-weight reduction was around 20–21%, with some analyses reaching approximately 22.5%. Those are averages across a diverse population; individual results varied, and the trial was conducted alongside a reduced-calorie diet and increased physical activity.

In a subsequent head-to-head study, SURMOUNT-5, Mounjaro produced greater average weight loss than semaglutide 2.4 mg over 72 weeks in adults with obesity who did not have type 2 diabetes. NICE considered this evidence when recommending tirzepatide in its appraisal TA1026, published in December 2024. The NICE recommendation covers adults with a BMI of 35 or above plus at least one weight-related comorbidity; lower thresholds apply for some ethnic backgrounds under UK guidance.

It is also worth understanding what the trials measured: average percentage weight loss in people who completed the programme with lifestyle support. They are not a prediction for any individual. A prescriber can help you think about what realistic expectations look like for your situation. Our Mounjaro weight loss results page goes through the evidence in more depth.

Side effects the Mounjaro jab can cause and when to get help

The most commonly reported side effects are gastrointestinal. Nausea tends to be the one people notice first, usually appearing in the days after a new dose step and fading as the body adjusts. Loose stools, constipation, indigestion, burping and a general sense of fatigue in the first week or two also appear regularly in reported experience and in the trial data. These effects are related to slowed gastric emptying and typically ease considerably once you settle at a given dose. Drinking enough water and eating smaller meals helps most people manage the transition.

Two situations need prompt medical attention. Severe, persistent stomach pain that radiates toward the back (with or without vomiting) can be a sign of pancreatitis, a serious but infrequent side effect. The MHRA highlighted this in a safety update in January 2026 and advises stopping the medicine and seeking urgent care. Separately, signs of a significant allergic reaction (face or throat swelling, difficulty breathing) require emergency help. You can report any suspected side effect via the MHRA Yellow Card scheme. Our page on Mounjaro and joint pain covers some of the less-discussed physical effects if that is relevant to you.

Mounjaro is not suitable for use during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for anyone under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma) require a careful prescriber conversation before starting. A full contraindication check is part of every clinical assessment.

Getting Mounjaro jabs: NHS routes and private alternatives

NHS access to tirzepatide is being phased in gradually under NICE TA1026. As of June 2025, the first cohort (adults with a BMI of 40 or above plus four or more qualifying conditions) can receive it through GP practices participating in the new QOF arrangement, though participation varies by practice. The second cohort (BMI 35–39.9 plus four or more conditions) became eligible from June 2026. Waiting times and local availability differ significantly, and all NHS patients must take part in wrap-around diet and activity support.

Many people either do not yet meet the NHS criteria or would prefer not to wait. A private prescription through a regulated online pharmacy is the alternative, subject to clinical suitability. If you are considering that route, the most important check is whether the pharmacy appears on the GPhC register, any legitimate dispensing pharmacy in England, Scotland and Wales must be listed. Sellers offering these jabs without a prescription or through social media with unusually low prices are a serious safety risk; fake pens have been found in the UK supply chain and have caused hospitalisations.

For a fuller picture of the private route and what a responsible service includes, the Mounjaro treatment overview covers eligibility, the consultation process and how treatment is managed. If cost is a factor in your thinking, our Mounjaro price comparison guide explains what legitimate private treatment typically costs and what to watch out for. When you are ready to explore whether these jabs are clinically suitable for you, you can check your eligibility with our prescribers, no obligation, no automatic approval, just a proper clinical assessment.